IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader.

Area of Science:

• Oncology
• Molecular Biology
• RNA Biology

Background:

• Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is known to regulate cell metabolism.
• Emerging evidence suggests a role for IGF2BP2 in cancer, but the mechanisms remain unclear.
• Upregulation of IGF2BP2 correlates with poor outcomes in pancreatic cancer patients.

Purpose of the Study:

• To investigate the role and mechanism of IGF2BP2 in pancreatic cancer pathogenesis.
• To elucidate the interaction between IGF2BP2 and long non-coding RNAs (lncRNAs).
• To explore the potential of targeting the IGF2BP2-lncRNA axis for cancer therapy.

Main Methods:

• Analysis of IGF2BP2 expression in pancreatic cancer patient data.
• Cell proliferation assays following IGF2BP2 knockdown (KD) or knockout (KO).
• RNA immunoprecipitation (RIP) and RNA pull-down assays to confirm IGF2BP2-lncRNA interaction.
• Xenograft models to assess the impact of DANCR on tumor growth.
• N6-methyladenosine (m6A) modification analysis and mutagenesis assays.

Main Results:

• IGF2BP2 upregulation is linked to poor prognosis in pancreatic cancer and its suppression inhibits cell proliferation.
• IGF2BP2 directly interacts with and stabilizes the lncRNA DANCR, enhancing its expression.
• DANCR promotes pancreatic cancer cell proliferation and stemness-like properties.
• IGF2BP2 acts as an m6A reader for DANCR, stabilizing the RNA.
• Knockdown or knockout of DANCR suppresses tumor growth in vivo.

Conclusions:

• IGF2BP2 promotes pancreatic cancer progression by stabilizing the m6A-modified lncRNA DANCR.
• The IGF2BP2-DANCR axis plays a critical role in promoting cancer stemness and pancreatic cancer pathogenesis.
• Targeting the IGF2BP2-DANCR interaction represents a potential therapeutic strategy for pancreatic cancer.